How Big Pharma hurt biotech; EMA's CHMP gives nod to GSK vax;

@FierceBiotech: Humans to test T-cell treatment that subdued canine lymphoma. More | Follow @FierceBiotech

@JohnCFierce: You gotta love the hep C arena right now. $VRTX up, $IDIX down, $GILD wounded. Like 3-D chess: One bad or good move changes the whole game. | Follow @JohnCFierce

@RyanMFierce: As one might expect, more good questions than good answers on the $GILD call this A.M. | Follow @RyanMFierce

@FierceMedDev: Profits at Medtronic down 21%. Article via @the_irish_times | Follow @FierceMedDev

> Forbes contributor Avik Roy explains how Big Pharma is to blame for biotech companies' inability to bring drugs to market without a partnership. Article

> The European Medicines Agency’s CHMP has given a nod to GlaxoSmithKline’s ($GSK) meningitis vaccine Nimenrix, recommending approval in the EU. Report 

> Alexza Pharmaceuticals ($ALXA), a Mountain View, CA-based developer of pain drugs, said today that it has priced a public offering to raise $22 million. Release

Pharma News

@FiercePharma: Risperdal didn't cause one man's diabetes, but J&J didn't do enough to warn his doctor, jury finds--Bloomberg. Story | Follow @FiercePharma

> AZ sells discounted cancer drug directly to patients. News

> Finding study flaws, EMA backpedals on Trasylol suspension. Story

> J&J pulls infant Tylenol on dosing-system issue. More

And Finally… DNA robots could be enlisted to search and attack diseases. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.